Kingsview Wealth Management LLC Makes New Investment in Humana Inc. $HUM

Kingsview Wealth Management LLC bought a new position in shares of Humana Inc. (NYSE:HUM) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 12,250 shares of the insurance provider’s stock, valued at approximately $2,995,000.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Humana by 8.9% in the first quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider’s stock valued at $3,697,222,000 after purchasing an additional 1,143,662 shares during the period. Dodge & Cox increased its holdings in Humana by 5.5% in the first quarter. Dodge & Cox now owns 10,755,215 shares of the insurance provider’s stock valued at $2,845,830,000 after buying an additional 557,175 shares in the last quarter. Pzena Investment Management LLC raised its holdings in Humana by 6.5% during the second quarter. Pzena Investment Management LLC now owns 4,076,667 shares of the insurance provider’s stock worth $996,664,000 after purchasing an additional 247,744 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Humana by 1.9% during the 2nd quarter. Geode Capital Management LLC now owns 3,130,829 shares of the insurance provider’s stock worth $762,233,000 after buying an additional 57,267 shares during the last quarter. Finally, Davis Selected Advisers raised its position in Humana by 3.3% during the first quarter. Davis Selected Advisers now owns 2,331,343 shares of the insurance provider’s stock worth $616,873,000 after acquiring an additional 74,434 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Stock Up 0.2%

NYSE HUM opened at $234.55 on Wednesday. Humana Inc. has a 12 month low of $206.87 and a 12 month high of $315.35. The company’s 50 day simple moving average is $268.77 and its 200 day simple moving average is $257.69. The company has a market capitalization of $28.21 billion, a P/E ratio of 18.00, a PEG ratio of 1.71 and a beta of 0.42. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, November 5th. The insurance provider reported $3.24 earnings per share for the quarter, beating analysts’ consensus estimates of $2.95 by $0.29. Humana had a return on equity of 13.67% and a net margin of 1.28%.The business had revenue of $32.65 billion for the quarter, compared to the consensus estimate of $31.99 billion. During the same quarter in the previous year, the company posted $4.16 earnings per share. Humana’s revenue for the quarter was up 11.1% compared to the same quarter last year. Equities research analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.5%. The ex-dividend date of this dividend is Friday, December 26th. Humana’s dividend payout ratio is currently 33.18%.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on HUM shares. Wall Street Zen downgraded shares of Humana from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Piper Sandler lowered their price target on shares of Humana from $288.00 to $272.00 and set a “neutral” rating for the company in a report on Thursday, July 31st. Royal Bank Of Canada increased their price target on Humana from $283.00 to $322.00 and gave the stock an “outperform” rating in a research note on Thursday, August 21st. Sanford C. Bernstein raised their target price on shares of Humana from $269.00 to $341.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Finally, Barclays decreased their price objective on shares of Humana from $315.00 to $245.00 and set an “equal weight” rating for the company in a research note on Friday, October 3rd. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $298.39.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.